BioAgilytix is honored to be named the 2014 CRO of the Year by the Triangle Business Journal in their 2014 Life Sciences Awards! This award recognizes BioAgilytix’s tremendous growth over the past year, which includes a growing team of senior-level scientists, expanded lab facilities, and many new platform technologies. Thanks to all of our happy clients for making this possible. As a part of our recognition, the Business Journal has posted a brief Q&A with our CEO, Jim Datin, on their website (link), and you can also find the content below:
Name: Jim Datin
CEO Age: 51
Firm Age: 6
Company Description: BioAgilytix is a leading bioanalytical contract research organization (CRO) that supports the development of novel therapeutic biologics and biosimilars. Located in Research Triangle Park, North Carolina, BioAgilytix specializes in large-molecule bioanalysis providing critical insight into the safety, efficacy, and mechanism of action of drug candidates throughout the clinical trial process. BioAgilytix is an engaged and energetic partner committed to delivering exceptional value and veteran expertise through a collaborative process that consistently results in successful projects.
What’s was the company’s biggest accomplishment in the past 12 months:
BioAgilytix was founded by senior-level scientists who identified an industry trend towards the outsourcing of bioanalytical testing, a complex and costly area of therapeutic development. By adhering to a highly-focused business model which offers answers to unmet needs within this niche sector of pharmaceutical development, BioAgilytix has been able to grow rapidly. In the past 12 months, our organic growth has been supplemented by a new financial partner, Riverside Partners, who has deep experience and a long history of investing in healthcare companies. They have enabled BioAgilytix to significantly grow our services, capabilities, and capacity.
Please explain the driving forces of your company’s growth in the past year?
BioAgilytix is capitalizing on several sweeping trends in the pharmaceutical and biotechnology industries. Companies are outsourcing ~45% of global R&D spending as a cost-effective alternative to capital intensive investments in research equipment, personnel, and facilities; and they have been shifting their focus to biologics, such as therapeutic proteins, monoclonal antibodies, and vaccines. The scientific skill set needed for large molecule development is distinctly different than the small molecule drugs that have dominated the pharmaceutical industry to this point. There is a shortage of scientists with biologics expertise, and in particular, the knowledge needed to do the science under strictly regulated quality systems. BioAgilytix has attracted top talent from pharmaceutical companies and other CROs to field a workforce that is uniquely apt at solving problems within the current context of the industry.
Complete the following statement: Since the inception of the company, the firm is most proud of …. Maintaining a remarkably high level of post-schooling experience among our scientific and quality teams, at 15+ years.